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Gprotein-coupled receptors (GPCRs) represent amajor focus
in functional genomics programs and drug development
research, but their important potential as drug targets contrasts
with the still limited data available concerning their activation
mechanism. Here, we investigated the activation mechanism of
the cholecystokinin-2 receptor (CCK2R). The three-dimen-
sional structure of inactive CCK2R was homology-modeled on
the basis of crystal coordinates of inactive rhodopsin. Starting
from the inactive CCK2R modeled structure, active CCK2R
(namely cholecystokinin-occupied CCK2R) was modeled by
meansof steeredmoleculardynamics ina lipidbilayerandbyusing
availabledata fromotherGPCRs, includingrhodopsin.Bycompar-
ing the modeled structures of the inactive and active CCK2R, we
identified changes in the relative position of helices and net-
works of interacting residues, which were expected to stabilize
either the active or inactive states of CCK2R. Using targeted
molecular dynamics simulations capable of converting CCK2R
from the inactive to the active state, we delineated structural
changes at the atomic level. The activationmechanism involved
significantmovements of helices VI andV, a slightmovement of
helices IV and VII, and changes in the position of critical resi-
dues within or near the binding site. Themutation of key amino
acids yielded inactive or constitutively active CCK2R mutants,
supporting this proposed mechanism. Such progress in the
refinement of the CCK2R binding site structure and in knowl-
edge of CCK2R activation mechanisms will enable target-based
optimization of nonpeptide ligands.
The superfamily of G protein-coupled receptors (GPCRs)5
represents a large and diverse family of seven transmembrane
helix proteins. Because they are involved in all physiological
processes, GPCRs are targeted by 50% ofmarketed drugs. How-
ever, these drugs address only a small fraction of the GPCR
repertoire. GPCRs represent a major focus in functional
genomics programs and drug development research, but their
important potential as drug targets contrasts strongly with the
very limited data available regarding their activation mecha-
nism. The activation of GPCRs is generally explained by the
extended ternary complex model whereby the population of
receptors exists as an equilibrium between inactive and active
states (1). According to this model, the active conformation of
the receptor may be stabilized or induced by agonists. The
extended ternary complex model for GPCRs is based on and
sustained by the discovery of engineered constitutively active
mutants, namely mutants that produce ligand-independent
signaling (1). Constitutively active GPCR mutants naturally
exist in humans and can cause diseases (2). Interestingly, con-
stitutive GPCR signaling can be inhibited or attenuated by a
class of therapeutic agents named inverse agonists (2, 3).
The cholecystokinin (CCK)-2 receptor (CCK2R), previously
named the CCKB/gastrin receptor, belongs to family I of
GPCRs, which includes rhodopsin (4–6). It binds both chole-
cystokinin and gastrin, two structurally related neuropeptides
with similar high affinities. CCK2R is expressed in the central
nervous system and in the gut, where it represents the predom-
inant CCK receptor subtype. CCK2Rmediates a wide spectrum
of CCK- and gastrin-induced biological effects, including anx-
iety, pain perception, gastric acid secretion, growth, and differ-
entiation of the gastric mucosa (4, 7). Converging studies have
documented that activation of wild-type CCK2R and/or
expression of a constitutively active variant may contribute to
human diseases (8, 9). These new findings have generated con-
siderable interest in the identification of antagonists of CCK2R.
To date, a large panel of chemically distinct CCK2R antagonists
have been discovered and used to assess the functionsmediated
by CCK2R in animals and humans (10). Furthermore, several of
these compounds have reached clinical evaluation stages for
indications such as anxiety and panic disorders, sleep disorders,
drug dependence, pain, gastroesophagus reflux, and gastric
secretion disorders (10). However, some reference molecules
believed to be pure antagonists turned out to be endowed with
some agonist activity in the stomach and pancreas as well as
cells expressing CCK1R or CCK2R (11–13). On the other hand,
reports on the expression of constitutively active receptors in
digestive cancers and on potential therapeutic relevance for
neuroendocrine tumors highlighted the need to identify inverse
agonists able to reverse basal constitutive activity of CCK2R
(14).
Target structure-based design of new ligands requires iden-
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tification of the receptor binding site and determination of the
activationmechanism.Toward this aim, our grouphas progres-
sively delineated the binding site of CCK2R using site-directed
mutagenesis combined with molecular modeling approaches
(15–17).We identified several aromatic residues belonging to a
network presumably critical for CCK2R activation (18). In this
last study, differential motion of amino acid side chains within
the binding pocket was observed upon in silico binding of dif-
ferent nonpeptide ligands that present distinct pharmacologi-
cal features. Nevertheless, due to the intrinsic limitations of the
modeling procedure used, no global change in CCK2R confor-
mation was observed (18).
The aim of the present study was to increase our knowledge
of themolecular mechanisms whereby CCK2R is activated. For
this purpose, three-dimensional models of inactive and active
CCK2R were constructed on the basis of available structural
data. These modeled structures were studied using unre-
strained molecular dynamics simulations (MDs) in an explicit
water-lipid environment. By comparing averaged modeled
structures, we identified changes in the relative positions of
helices and networks of interacting residues expected to stabi-
lize either active or inactive states of CCK2R. The activation
mechanism of the receptor was further investigated using tar-
geted molecular dynamics simulations and site-directed
mutagenesis.
EXPERIMENTAL PROCEDURES
Molecular Modeling
Modeling of the “Inactive” CCK2R Structure (CCK2R°)—The
structure of bovine rhodopsin (Protein Data Bank code 1U19)
crystallized in the dark was used as structural template for the
homology modeling of the CCK2R receptor (19). Alignment of
human CCK2R sequence and bovine rhodopsin sequences was
carried out using the ClustalW multiple alignment program
(20). Loops connecting transmembrane helices were modeled
using the ab initio modeling program MODLOOP (21). The
third intracellular loop was not included in the modeled struc-
ture. The crude homology model was refined using AMBER8
(available on the World Wide Web) by means of 1000 steps of
steepest descent energyminimization followed by 2000 steps of
conjugate gradient energy minimization while all C carbons
were harmonically restrained to their initial positions. This
procedure allowed readjustment of covalent bonds and van der
Waals contacts without changing the overall conformation of
the protein. Themodelwas then refined bymolecular dynamics
simulations in an explicit lipid bilayer. It was neutralized by the
addition of 17 chloride ions and placed in a rectangular box
(78 80 78 Å in size) containing a lipid bilayer (153 mol-
ecules of palmitoyloleoylphosphatidylcholine and 8708 mole-
cules of water in addition to the receptor structure), resulting in
a final density of 1.0 g/cm. MD simulations at 300 K and con-
stant pressure (1 atm) with anisotropic scaling were then run
for 1ns using the SANDER module in AMBER 8. The cut-off
distance for the nonbonded interactions was 9 Å, and periodic
boundary conditions were applied. Electrostatic interactions
were represented using the smooth particle mesh Ewald
methodwith a grid spacing of1Å. The coupling constants for
the temperature and pressure baths were 1.0 and 0.2 ps, respec-
tively. SHAKEwas applied to all bonds involving hydrogen, and
an integration step of 2 fswas used throughout. The nonbonded
pair list was updated every 10 steps. The simulation protocol
involved a series of progressive energy minimizations followed
by a 20-ps heating phase and a 250-ps equilibration period,
duringwhich secondary structure restraints were applied to the
transmembrane helices. These restraints were removed during
the following 750 ps of data collection. Systemcoordinateswere
saved every 2 ps for analysis.
Modeling of the “Active” CCK2R Structure (CCK2R*)—The
CCK2R° homology model obtained from the rhodopsin crystal
was not directly suitable for docking purposes, because the
ligand-binding pocket of inactive rhodopsin is remarkably nar-
row (19). We therefore refined the rhodopsin-based CCK2R°
model in order to obtain a model of active CCK2R. Since it has
been proposed that the conserved tryptophan belonging to the
CWPFFmotif in helix VI changes its orientationwith respect to
the membrane plane during activation, being perpendicular in
the inactive form and parallel in the active form, the side chain
of Trp-6.48 wasmanually rotated to adopt the latter conforma-
tion (22, 23). We then docked CCK4 into this crude model,
taking into account all amino acids and key interactions iden-
tified in the course of binding site studies (15, 24, 25) and ran
steeredmolecular dynamics simulations. In fact, steeredmolec-
ular dynamics were first performed in the presence of CCK4,
because contacts were only available for the last four residues of
CCK, which correspond to the ligand binding region. Then the
N-terminal extension of CCK was added. The simulation was
performed in vacuo with a small spherical shell of 450 TIP3P
water molecules centered around His-207. The radius of this
water shell was 20 Å, ensuring the solvation of the extracellular
portion of the helices and the extracellular loops. These water
molecules were first energy-minimized, and then waters and
protein residues were allowed to relax. In each case, 1000 steps
of steepest descent were followed by 2000 steps of conjugate
gradient energy minimization. The final coordinate sets were
used as input for the subsequent steered MD simulations.
SHAKE was used for all bonds, and the integration time step
was 2 fs. The cut-off was 12Å, and a distance-dependent dielec-
tric functionwas used. The list of nonbonded pairs was updated
every 25 steps, and coordinateswere saved every 2 ps for further
analysis.
The second run of 500-ps steered molecular dynamics sim-
ulations consisted of applying distance constraints by means of
a harmonic potential as indicated in Table 1. TheC carbons of
helices I–III were restrained by positional constraints of 1 kcal/
mol Å during all of the simulation.
Once the desired distances were attained, CCK4 was substi-
tuted by CCK in the binding site. The final model was then
refined by 1 ns of unrestrained MDs in an explicit lipid bilayer
using the protocol described above for the CCK2R°. Finally,
CCK was removed from the complex, and the free active con-
formation of CCK2R (CCK2R*) was also simulated by 1 ns of
MD in a lipid environment. Although CCK2R* is energetically
less stable than CCK2R°, the CCK2R* model did not relax back
to CCK2R° during MD, because this back conversion would
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require a microsecond time scale and could not be observed
with MD simulations in the nanoseconds time scale.
In Silico Conversion of CCK2R° to CCK2R* Using Targeted
Molecular Dynamics Simulations
The targeted molecular dynamics (TMD) approach used the
standard implementation recently incorporated into AMBER
(version 8.0) (available on theWorldWideWeb), which allows
solventmolecules tomove freely and follow the dynamics of the
protein. A restraint was defined in terms of a mass-weighted
r.m.s. superposition to the final reference structure (target,
CCK2R*) and applied in the force field as an extra harmonic
potential energy term of the following form,
E  0.5kr x Nr.m.s.d. t.r.m.s.d.2 (Eq. 1)
where E is the biasing potential energy in kcal/mol during the
TMD simulation, kr is the force constant, N is the number of
atoms, r.m.s.d. is the root mean square deviation from the tar-
get structure, and t.r.m.s.d. is the desired root mean square
deviation value. The initial value of the desired root mean
square deviation was set as the root mean square deviation
between the initial and target structures (CCK2R° andCCK2R*,
respectively), and during the simulation, the desired root mean
square deviation value was gradually decreased to 0. Only the
heavy atoms of the protein were considered in the r.m.s. defini-
tion. A force constant of 0.50 kcal/molÅover 0.5 ns appeared
sufficient to find a low energy path leading from the simulated
structure to the target structure.
Site-directed Mutagenesis of CCK2R and Transfection of
COS-7 Cells
All mutant receptor cDNAs were constructed by oligonucle-
otide-directed mutagenesis (QuikChangeTM site-directed
mutagenesis kit; Stratagene) using human CCK2R cDNAs
cloned in the pRFNeo vector as template. The presence of
desired and the absence of undesired mutations were con-
firmed by automated sequencing of the complete CCK2R cod-
ing sequence (Applied Biosystems). COS-7 cells (1.5  106)
were plated onto 10-cm culture dishes and grown inDulbecco’s
modified Eagle’s medium (DMEM) containing 5% fetal calf
serum in a 5% CO2 atmosphere at 37 °C. After overnight incu-
bation, cells were transfected with 1 g/plate of pRFNeo vec-
tors containing the cDNA for the wild-type or mutated CCK2
receptors, using a modified DEAE-dextran method. Cells were
transferred to 24-well plates 24 h after transfection at a density
of 150,000 cells/well for inositol phosphate determination and
5000–10,000 cells/well for binding assays.
Inositol Phosphate Production Determination
Approximately 24 h after transfer to 24-well plates and
following overnight incubation in DMEM containing 2
Ci/ml myo-2-[3H]inositol (specific activity 10–25 Ci/ml;
PerkinElmer Life Sciences), transfected cells were washed with
DMEM and incubated for 30min in 1ml/well DMEM contain-
ing 20 mM LiCl at 37 °C. Cells were washed with Ins-P buffer at
pH 7.45: phosphate-buffered saline containing 135 mM NaCl,
20 mM HEPES, 2 mM CaCl2, 1.2 mM MgSO4, 1 mM EGTA, 10
mM LiCl, 11.1 mM glucose, and 0.5% bovine serum albumin.
Cells were then incubated for 60 min at 37 °C in 0.3-ml Ins-P
buffer alone or with CCK in the presence of increasing concen-
trations of synthetic ligands. Reactions were stopped by adding
1 ml of methanol/HCl to each well, and contents were trans-
ferred to a column (Dowex AG 1-X8, formate form; Bio-Rad)
for the determination of Ins-P. Columns were washed twice
with 3ml of distilled water and twice with 2ml of 5 mM sodium
tetraborate, 60 mM sodium formate. The content of each col-
umn was eluted by the addition of 2 ml of 1 M ammonium
formate, 100mM formic acid. Radioactivity of 1ml of the eluted
fraction was evaluated using a liquid scintillation counter
(Packard Instrument Co.). Values for Ins-P accumulation were
normalized to a constant number of expressed receptors (1
pmol) and were expressed as -fold number of the basal value
achieved with the wild-type CCK2R. Mock cells were trans-
fected with a pRFNeo noncoding vector.
Receptor Binding Assay
Approximately 24 h after transfer of transfected cells to
24-well plates, the cells were washed with phosphate-buffered
saline, pH 7.4, containing 0.1% bovine serumalbumin and incu-
bated for 60 min at 37 °C in 0.3 ml DMEM containing 0.1%
bovine serum albumin with an appropriate concentration of
high pressure liquid chromatography-purified 125I-BH-
(Thr,Nle)-CCK9 (specific activity 1600–2000 Ci/mmol) in the
presence or absence of unlabeledCCK.Cells werewashed twice
with cold phosphate-buffered saline, pH 7.4, containing 2%
bovine serum albumin, and cell-associated radioligandwas col-
lected by cell lysis with 0.1 N NaOH. The radioactivity was
directly counted in a  counter (Auto-Gamma; Packard Instru-
mentCo.). Receptor density (Bmax) andKdwere calculated from
homologous 125I-BH-(Thr,Nle)-CCK9 competition binding
experiments using Ligand software (Kell, Cambridge, UK). Ki
values were calculated using the nonlinear curve fitting soft-
ware GraphPad Prism (San Diego, CA).
RESULTS
Modeled Structure of Active CCK2R (CCK2R*)—Because
CCK2R is a member of the family I of rhodopsin-like GPCRs,
the three-dimensionalmodel of the inactive state of theCCK2R
(CCK2R°) was constructed by homology modeling using coor-
dinates from the inactive rhodopsin crystal isolated in the dark
(19). To obtain CCK2R*, the agonistCCK2R complex was
modeled (Fig. 1). The procedure of modeling, which is
described in detail under “Experimental Procedures,” included
the following main steps: rotation of conserved Trp-6.48 side
chain (22); docking of CCK4 followed by steered molecular
dynamics simulation in vacuum; steered molecular dynamics
simulation based on constrained distances indicated in Table 1
and derived from published data on GPCR activation; and
refinement in a lipid bilayer (see Table 1 for references).
As illustrated in Fig. 2, after the equilibration period, pro-
gression of the r.m.s. deviations of the coordinates of the C
atoms relative to the average structure showed a notably stable
behavior, reflecting that the overall architecture of the protein
was preserved for the whole length of the simulation for
both CCK2R° and the CCK2R*CCK complex. Furthermore,
Human Cholecystokinin Receptor-2 ActivationMechanism
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inter-C distances used during steered molecular dynamics
were maintained in the absence of external restraints (Table 1).
As a consequence of CCK docking and molecular dynamics
applied to the complex, the binding pocket of the initial rho-
dopsin-based model (CCK2R°) was enlarged to snugly accom-
modate CCK in a position that was in agreement with site-
directed mutagenesis data (see Table 3) (see Table 1 for
references). Indeed, the CCK binding pocket was mainly
formed by residues from transmembrane helices (Figs. 1 and 3).
Sulfated CCK-Tyr was well engaged by two hydrogen bonds
with Arg-1.35 and Tyr-1.39 and by stacking interactions with
His-7.39. The CCK-tryptophan was located in the hydropho-
bic/aromatic pocket formed by residues from helices III, VII,
and the first extracellular loop. The indole moiety of this resi-
due established aromatic contacts with Tyr-7.43 and hydro-
phobic contacts with Phe-120 in the first extracellular loop and
His-7.39. The CCK-methionine residue was placed between
helix VI and helix VII interacting with Val-6.51 and the C
carbon of Ser-7.45. The phenylalanine ring was located in a
hydrophobic/aromatic pocket composed of residues from dif-
ferent helices: Val-3.36, Met-4.57 and Tyr-4.60, Leu-5.46, and
Val-6.51 and Tyr-6.52. The aspartic acid residue accepted
hydrogen bonds from His-207 in the second extracellular loop
and the guanidinium group of Arg-6.58. The carbonyl group of
CCK amide accepted a hydrogen bond from Tyr-4.60 hydroxyl
oxygen, and CCK nitrogen amide donated a hydrogen to Asn-
6.55 carbonyl amide. The fact that all of these intermolecular
interactions were maintained after the equilibration period
confirmed the stability of themodeled complex (Table 1). After
the removal of CCK, the unboundCCK2R*was inserted into an
explicit lipid bilayer and subjected to molecular dynamics sim-
ulations, resulting in a stable trajectory (Fig. 2) and yielding the
refined CCK2R* model.
Comparison of the Modeled Structures of CCK2R° and
CCK2R*—In order to investigate the activation mechanism
of CCK2R, we first compared averaged structures of refined
CCK2R° and CCK2R* models. Actually, we assumed that
CCK2R naturally exists in an equilibrium between receptors
in the inactive (CCK2R°) and active state (CCK2R*) and that
specific intramolecular networks stabilize each conforma-
tion. In support of this assumption, we previously showed
that human wild-type CCK2R presents some degree of con-
stitutive activity (18).
FIGURE 1. Serpentine representation of human CCK2R.Main amino acids of the CCK2R binding site (indicated aswhite letters in filled black circles) as well as
those between which constraints were applied (indicated as black letters in empty circles; see Table 1) during CCK2R* modeling are numbered.
TABLE 1
Distances between amino acids used for generation of the
CCK2R* model
The desired values are given in parentheses.
Distances CCK2R*CCKcomplexa Reference
Å
Forced during the steered molecular
dynamics simulation
Tyr-4.60 OH CCK-Phe O (2.8–3.2 Å)b 3.1 0.3 16
Asn-6.55 OD1 CCK-Phe N2 (2.8–3.2 Å)b 2.9 0.1 16
Arg-6.58 NH1 CCK-Asp-8 OD1 (2.8–3.2 Å)b 2.8 0.1 16
His-207 NE2 CCK-Asp-8 OD1 (2.8–3.2 Å)b 2.9 0.1 16
Met-4.57 SD centroid CCK-Phe centroid (5 Å)b 5.6 0.5 24
Ile-156 C Arg-6.35 C (18.5 Å)c 18.3 0.5 47
Arg-3.50 C Tyr-7.53 C (19 Å)c 18.2 0.5 48
Tyr-7.53 OH Asn-1.50 OD1d 2.8 0.1 49
Asp-2.50 OD2 Asn-1.50 ND2d 2.9 0.1 49
Asp-2.50 OD2 Asn-7.49 ND2d 3.0 0.2 49
Nonforced
His-7.39 centroid CCK-SO3H(Tyr) centroid 4.2 0.3
Tyr-4.60 centroid CCK-Phe centroid 5.4 0.4
Tyr-7.43 centroid CCK-Trp centroid 5.0 0.3
a Mean distances S.D. obtained from the production part of theMD in an explicit
membrane.
b Applied during the first 500 ps of the simulations. The force constant was fixed to
10 kcal mol1 Å2.
c Applied in the successive 500 ps of the simulations. In this case, the force constant
was progressively increased 2 kcal mol1 Å2 during five consecutive runs of 100
ps each.
d Applied in the last 100 ps.
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In silicoCCK2R° toCCK2R* conversion brought together the
upper parts of helices VI and III (Table 2) and caused clockwise
rotation of helix VI (observed from extracellular space). Fur-
thermore, in CCK2R*, the cytoplasmic ends of helices VI and
VII weremore distant from the end of helix III than in CCK2R°,
which can be inferred from two distances, one between the
Asn-6.55 C atom and Ile-156C in IC2 and the other between
C of Arg-3.50 and Tyr-7.53 (Table 2).More detailed examina-
tion of refined CCK2R structures also revealed changes in the
position of the side chain of several amino acids and in the
nature of contacts, particularly from helices III, IV, V, VI, and
VII. Most striking was the rear-
rangement of the molecular net-
work accompanying rotation of
conserved Trp-6.48 from a position
inside the binding pocket in
CCK2R° to a position outside this
binding pocket in CCK2R* (Fig. 4).
In fact, in the resting state, Trp-6.48
interacted with Val-3.36, Met-3.32,
Ser-7.45, Phe-6.44, and Val-6.51. In
CCK2R*, Trp-6.48 no longer inter-
acted with the aforementioned resi-
dues, except Phe-6.44, but estab-
lished new interactions, such as
those with Tyr-6.52 and Phe-5.47
(Fig. 4, A and B). Another conse-
quence of rotation and tilting of
helix VI during activation was that
Cys-6.47 and Val-6.51 were located
in the binding pocket and occupied
the previous position of Trp-6.48 in
CCK2R°.
Regarding helix IV, although its movement was small, its
extracellular end was brought closer to that of helix VI as a
result of its rotation and tilting. Indeed, in CCK2R*, Tyr-4.60
formed a hydrogen bond with Asn-6.55, whereas in CCK2R°,
Tyr-4.60 established contacts withMet-4.57 and Leu-5.42 (Fig.
4C).
Concerning helix V, comparison of theCCK2R* andCCK2R°
structures suggested that this helix underwent a concerted
movement to allow helix VI to rotate clockwise during activa-
tion. In fact, in CCK2R*, Trp-6.48 and Tyr-6.52 have moved to
positions previously occupied by Phe-5.47 and Leu-5.43,
respectively, in CCK2R° (Fig. 4D).
Finally, helix VII was positioned 2 Å higher in CCK2R* rela-
tive to CCK2R°. This motion disrupted a network of interac-
tions present in CCK2R° between Tyr-7.43, His-7.39, andMet-
3.32. All of these observations suggested that interhelical
contacts described above between helices III, IV, V, VI, and VII
may be critical for CCK2R activation.
Delineation of the CCK2R° to CCK2R* Conversion by Tar-
geted Molecular Dynamics Simulations—The comparison
betweenmodeled structures of CCK2R° andCCK2R* suggested
that observed changes in amino acid andhelix positions are part
of the activation mechanism of CCK2R. However, these data
could not answer the questions of how, at a molecular level, the
changes involving movements of helices and amino acids actu-
ally proceed, in which order they occur, and how they are coor-
dinated. To answer these questions, TMD, an in silicomethod
that can simulate intricate conformational changes in proteins
as the pathway between two conformations, was applied to
CCK2R (27).
In these in silico experiments, we observed that a force con-
stant of 0.50 kcal mol1 Å2 over 500 ps was sufficient to
achieve the CCK2R° to CCK2R* conversion, as can be inferred
from the final value of the r.m.s. deviation of the backbone
atoms. The TMD showed that the rotation of the side chain of
Trp-6.48 is a consequence of a completed coordinated tilting
FIGURE 2. Evolution of the root mean square deviations (RMSD) of the C atoms with respect to the
calculatedaveragestructure. Thick line, CCK2R°; thin line, CCK2R* in theabsenceof ligand;dotted line, CCK2R*
in the presence of CCK. Each line is made up of 240 individual points from the last 480 ps of the molecular
dynamics trajectory.
FIGURE 3. Schematic representation of the binding site for CCK in CCK2R.
Sideviewof the three-dimensional CCK2R*CCKcomplex. TheCCK2RC trace
is displayed as a green ribbon. For clarity, only amino acid side chains belong-
ing to or close to the binding site are labeled and shown as sticks. Relevant
hydrogen bonds are shown as dotted lines. CCK is displayed as sticks, and
carbon atoms are colored in orange. Amino acids between which constraints
were applied to generate CCK2R* are labeled in red.
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and rotation of helix VI andmovement of helix V. As a criterion
for the tilting of helix VI, two distances, the first one between
the C carbons of Asn-6.55 and Tyr-189 (not shown) and the
second one between the C carbons of Val-6.51 and Met-3.32,
respectively, were monitored. The latter also allowed measure-
ment of rotation of helix VI, whereas the rotation of the Trp-
6.48 side chain was followed by the Chi1 torsion angle. We
found that the tilting and rotation movement of helix VI was
progressive, as can be deduced from the evolution of the Val-
6.51 C toMet-3.32 C distance (Fig. 5). Furthermore, confor-
mational transition of Trp-6.48 side chain from g to twas not
direct; actually, as shown in Fig. 5, an intermediate of120°was
maintained from 260 to 420 ps of simulation. This intermediate
state was reached after 260 ps of simulation and occurred once
hydrogen bonding interaction between the indole of Trp-6.48
and the Ser-7.45 hydroxyl started to be disrupted, an event that
was simultaneouswith the beginning ofmovement of the upper
part of this helix. In other words, the hydrogen bonding inter-
action betweenTrp-6.48 and Ser-7.45 impeded rotation of Trp-
6.48, and the movements of helix VI and VII appeared partially
coordinated. Visual inspection of the conformation changes
also revealed that the position of helix Vwas responsible for the
stabilization of the intermediate state. Indeed, from 1 to 260 ps,
helixVmoved but not sufficiently to accommodate the position
of helix VI in the active state. At 420 ps, Phe-5.47 and Leu-5.43
reached their final position in the active state, and Trp-6.48
could complete its rotation to occupy its disposition parallel to
the membrane (Fig. 6). The targeted molecular dynamics also
revealed an important role for Tyr-6.52 in relation to coordina-
tion of helix V and VI movements. The tilting movement
undergone by the extracellular end of helix VI from 1 to 125 ps
appeared to be sufficient to locate Tyr-6.52 in the position
occupied by Phe-5.47 in CCK2R°.
Thus, at this time, Phe-5.47 had
already moved to an orientation
close to that of the active one. This
suggests that Tyr-6.52 acts as a
wedge in the coordinated rotation
of Phe-5.47 and Trp-6.48 and, as a
consequence, in the coordinated
movements of helices V and VI. At
last, TMD confirmed that helix III
did not significantly move during
CCK2R° to CCK2R* conversion, a
result in agreement with the con-
straining hydrophobic interactions
of Trp-6.48 withMet-3.32 and Val-
3.36, which were disrupted only
once rotation of Trp-6.48was com-
pleted (at 460 ps). A schematic rep-
resentation of helix movements
occurringduringCCK2Ractivation is
shown in Fig. 7.
Experimental Evidence for the
Importance of Aromatic/Hydro-
phobic Residues in the CCK2R
Activation—To verify the role of the
aforementioned residues in the acti-
vation mechanism, they were
mutated, and the basal activities of
the resulting mutants were deter-
mined by measuring inositol phos-
phate production in transfected
COS-7 cells in the absence of ago-
nist stimulation (basal activity) and
the presence of CCK. By doing so,
we expected thatmutation of amino
FIGURE 4. Changes in networks in CCK2R° and CCK2R* conformations. The models presented here were
extracted from averaged minimized structures obtained from the last 250 ps of the simulations. A and B, detail
showingthepositionofTrp-6.48anditsneighboringresidues, inunoccupiedCCK2R° (A,cyan)andCCK2R*(B,green),
respectively. The C trace is shown as a ribbon, Trp-6.48 is enveloped by a semitransparent solvent-accessible
surface colored in pink, and the interacting residues are displayed as sticks. The hydrogen bond between
Tyr-4.60 and Asn-6.55 is displayed. C and D, superposition of inactive (CCK2R°) and active (CCK2R*) conforma-
tions colored in blue and green, respectively. For clarity, important amino acids are displayed in two separated
panels. Relocation of amino acids in the helix V-VI interface discussed under “Discussion” is shown. Note that in
the CCK2R* conformation, Trp-6.48 occupied the position of Phe-5.47 in the inactive sate.
TABLE 2
Interhelical distances in the CCK2R* and CCK2R° conformations
Mean distances S.D. of the interhelical contacts measured in the production part
of the MDs in an explicit membrane (in Å).
CCK2R*CCK
complex CCK2R* CCK2R°
Å Å Å
Ile-156 C Arg-6.35 C 18.3 0.5 17.3 0.5 15.6 0.4
Arg-3.50 C Tyr-7.53 C 18.2 0.5 18.4 0.4 17.2 0.3
Val-6.51 CMet-3.32 C 9.1 0.3 8.8 0.3 11.9 0.5
Val-6.51 C Val-3.36 C 8.3 0.6 8.2 0.4 12.3 0.5
Tyr-4.60 C Asn-6.55 C 13.3 0.5 10.7 0.5 15.5 0.8
Tyr-4.60 OH Asn-6.55 OD1 6.5 0.5 3.1 0.4 8.2 0.7
Tyr-7.53 OH Asn-1.50 OD1 2.8 0.1 2.8 0.1 11.0 0.3
Asp-2.50 OD2 Asn-1.50 ND2 2.9 0.1 3.6 0.7 5.8 0.6
Asp-2.50 OD2 Asn-7.49 ND2 3.0 0.2 3.1 0.3 2.9 0.2
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acids that stabilize the receptor in the inactive state should gen-
erate constitutively activemutants, whereasmutation of amino
acids involved in intramolecular interactions stabilizing the
active form should producemutants devoid of basal activity. As
illustrated in Fig. 8, exchange of Val-3.36, Met-4.57, Leu-5.42,
Leu-5.43, Phe-5.47, and Trp-6.48 with an Ala yielded constitu-
tively active mutants, indicating that these amino acids are
required for stabilization of CCK2R°. Strikingly, mutants
V3.36A, L5.42A, L5.43A, and F5.47A displayed robust consti-
tutive activities, since inositol phosphate production in cells
transfected with these mutants represented 3–4-fold that of
cells transfected with wild-type CCK2R. Mutant W6.48A
exhibited a 2.5-fold enhanced activity relative to wild-type
CCK2R. Mutant M3.32A and Y7.43A showed a slight or a
marked constitutive activity, respectively. For comparison,
mutation E3.49A in the conserved (E/D)RY motif, previously
found to cause oncogenic activity of the CCK2R, showed a
2-fold increased activity relative to the wild-type CCK2R (26).
In contrast, mutation of Tyr-4.60, Phe-6.44, Asn-6.55, and Tyr-
6.52 produced CCK2Rmutants that exhibited no detectable or
significantly lower basal activity than that of wild-type CCK2R,
thus ascribing a role in the stability of the active state of the
receptor to these amino acids. On the other hand, mutation of
Ser-7.45 and His-7.39 did not change basal activity of CCK2R.
The consistency between biological data and structural
changes during the CCK2R° to CCK2R* transition was exam-
ined. Biological data showing constitutive activity of
mutants W6.48A, V3.36A, and M3.32A support the view
deduced from analysis of themodeled CCK2R° structure that
interactions between Trp-6.48 and Val-3.36/Met-3.32 in
FIGURE 5. Targeted molecular dynamics applied to conversion of CCK2R° to CCK2R*. Top, time evolution along the TMD simulations of the Chi1 torsion
angle of Trp-6.48. Bottom, distancebetween theC carbons of Val-6.51 andMet-3.32 (dotted upper line) andhydrogenbondingdistancebetween Trp-6.48 and
Ser-7.45 (thick lower line). Note that there is a correlation between the disruption of the hydrogen bond and the change in the torsion angle of Trp-6.48.
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CCK2R° stabilize this state. The biological data also suggest
that Leu-5.42 and Leu-5.43, which do not interact with Trp-
6.48 in CCK2R°, play a role in themaintenance of the inactive
state. To explain this result, we suggest that Leu-5.43 and
Phe-5.47 maintain CCK2R in its inactive state, because the
motion of these two residues is required for, and must pre-
cede, rotation of Trp-6.48 and Tyr-6.52. It is also worthy to
note that mutation of Ser-7.45, which appeared to be hydro-
gen-bound with Trp-6.48, did not produce a constitutive
CCK2R, indicating that disruption of a hydrogen bond was
not sufficient for CCK2R° to CCK2R* conversion. This result
fits with the view that an intermediate state was generated by
hydrogen bond disruption.
The finding that Y4.60F and N6.55A mutants lack basal
activity fits with the view that the hydrogen bonding interaction
between these two residues is important for the stability of
CCK2R* conformation. The hydrogen bond between Tyr-4.60
andAsn-6.55 in CCK2R* appears possible because the Tyr-4.60
side chain has moved to occupy the position of Leu-5.42 in the
CCK2R*, pushing it outside of the binding pocket. As a conse-
quence, interaction between Met- 4.57 and Leu-5.42 is dis-
rupted during CCK2R° to CCK2R* conversion. The roles of
Met-4.57 and Leu-5.42 in themaintenance of the CCK2R° con-
formation may be explained in this way. At last, pharmacolog-
ical experiments were carried out with all mutants to measure
their expression level, their binding properties, and their ability
to respond to CCK stimulation. A summary of results from
these experiments is presented in Table 3.
DISCUSSION
In this work, using in parallel state-of-the-art molecular
modeling and site-directed mutagenesis approaches, the
molecular mechanism of CCK2R activation was investigated
with respect to the activation of phospholipase C by measuring
inositol phosphate production. A number of amino acids that
participate in the activation of CCK2R by stabilizing either
active or inactive conformations of the receptorwere identified,
and a global mechanism of activation involving several key
FIGURE 6. Delineation of CCK2R° to CCK2R* conversion by targeted molecular dynamics simulation. Overlay of representative snapshots of the TMD
trajectory showing the evolution of positions of amino acids from transmembrane helices during CCK2R° to CCK2R* conversion. Transmembrane helices are
represented as ribbons, and, for clarity, only the side chain of some residues involved in CCK2R activation, Leu-5.43, Phe-5.47, Trp-6.48, Val-6.51, Ser-7.45, and
Tyr-6.52 are shown as sticks. The color code (blue3 orange3 pink3 green) corresponds to structures at 0, 260, 420, and 500 ps of simulation, respectively. A,
0 and 260 ps; B, 260 and 420 ps; C, 420 and 500 ps.
FIGURE 7. Schematic representation of helix movements during the transition from CCK2R° to CCK2R*. For clarity, transmembrane helices (TM) are
shownas cylinders. Blue corresponds to inactive state (CCK2R°),pink to an intermediate conformation (taken at 200ps) betweenCCK2R° andCCK2R*, andgreen
to the active state (CCK2R*) obtained from the TMD. Red arrows indicate movements of helices.
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amino acids within or near the binding site as well as move-
ments of transmembrane helices IV, V, VI, and VII was
deduced. We considered that CCK2R, like other G protein-
coupled receptors, naturally exists in an equilibrium between
receptors in the inactive conformation and receptors in active
conformation, the latter being responsible for constitutive
activity of the receptor. Previously, we demonstrated that wild-
type human CCK2R displays such a constitutive activity, since
it enhances production of inositol phosphates in COS-7 cells to
a level that is directly a function of the level of receptor expres-
sion at the cell surface (18). As demonstrated with other
GPCRs, we presumed that adequate mutation of amino acids
critical for the stabilization of the inactive state should generate
constitutively active mutants, whereas the mutation of amino
acids critical for the stabilization of the active state should yield
a receptor with zero or decreased basal activity. According to
this model, amino acids that appear to be involved in stabiliza-
tion of CCK2R° are Met-3.32, Val-3.36, Met-4.57, Leu-5.42,
Leu-5.43, Phe-5.47, and Trp-6.48, whereas those that stabilize
CCK2R* are Tyr-4.60, Phe-6.44, Tyr-6.52, and Asn-6.55.
Importantly, all analyzed mutants retained a good ability to
respond to the full agonist CCK. On the other hand, constitu-
tively active mutants displayed an
activity that remainedmoderate rel-
ative to the maximal CCK-induced
response.
One of themost significant struc-
tural changes occurring during
CCK2R activation concerns helix
VI, which undergoes a clockwise
rotation where the extracellular end
is tilted toward helix III. Targeted
molecular dynamics revealed that
helix VI movement is coordinated
with rotation of helix V and upper
movement of helix VII. As a conse-
quence of these movements, inter-
helical contacts change from the
inactive to active state, the most
remarkable being the molecular
network around the conserved
Trp-6.48.
Since the above mechanism of
CCK2R activation was deduced
from the in silico conversion of
CCK2R° to empty CCK2R* and the
role of the agonist is to stabilize
CCK2R*, the consistency of this
activation mechanism with the
mode of CCK binding to CCK2R*
must be considered. In helix VI,
Arg-6.58 and Asn-6.55 participate
in CCK binding. In empty CCK2R*,
the Arg-6.58 guanidium is associ-
ated with water molecules, whereas
Asn-6.55 is in tight interaction with
the Tyr-4.60 hydroxyl and thus con-
tributes to CCK2R* stabilization. In
the presence of CCK, the Arg-6.58 guanidium moves slightly
toward the binding cavity to interact with the side chain of
CCK-aspartic acid. Interestingly, following CCK binding, the
Asn-6.55–Tyr-4.60 bond dissociates, leaving the side chains of
these amino acids free to accommodate the CCK amide
through hydrogen bonds. As for CCK-Trp, its location between
helix III and VII through interactions with His-7.39 and Tyr-
7.43 contributes to the stabilization of helix VII in the upper
position as found in empty CCK2R*. In the absence of CCK, in
CCK2R*, helix VII position is locked by interactions between
His-7.39 and Tyr-7.43 withMet-3.32. Furthermore, in CCK2R*
an aromatic/hydrophobic pocket is enlarged due to the rotation
of amino acids surrounding Trp-6.48. CCK-Phe perfectly
accommodates, in this binding pocket formed by Val-3.36,
Met4.57 and Tyr4.60, Leu5.46, and Val6.51 and Tyr6.52 and
thus contributes to the stabilization of CCK2R*. Several amino
acids critical for CCK2R activation, such as Trp-6.48, Leu-5.42,
Leu-5.43, and Phe-5.47, are not in contactwithCCK, since their
side chains are directed outside the binding cavity in CCK2R.
All together, these data provide an original picture of how
CCK2R can adopt the active conformation on its own, with an
energy barrier between active and inactive conformations that
FIGURE 8. Effect of mutation of hydrophobic/aromatic residues on basal activity of CCK2R. Basal inositol
production inCOS-7 cells transiently expressingwild-type (WT) ormutatedCCK2R. Thevalue0 representsbasal
inositol phosphate production in cells transfected with mock plasmid, and it corresponds to about 300 dpm.
The value 1 represents basal inositol phosphate production in cells expressing the wild-type CCK2R, and it
corresponds to about 650 dpm. Values are calculated for 1 pmol of CCK2R variants as measured by binding
experiments. *,p 0.05; **,p 0.01; ***,p 0.001.Mutants that exhibit a significantly higher basal activity are
considered to be constitutively active. CCK-inducedmaximal production of inositol phosphates in COS-7 cells
transiently expressing wild-type or mutated CCK2R is reported on Table 3. Values are the means of 3–12
separate determinations.
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is probably small. Furthermore, they showhow the peptide ago-
nist, CCK, binds to CCK2R* to stabilize it through specific
interactions, some of which concern anchoring points, whereas
others serve tomaintain helices at critical positions in CCK2R*.
The above global structural changes observed duringCCK2R
activation are in line with those described or suggested with
other GPCRs using biochemical and biophysical techniques,
but they appear quantitatively smaller (28–30). Concerning
movements of helix VI, pioneering studies using electron para-
magnetic resonance analysis of spin-labeled rhodopsin have
revealed the proximity of helices III and VI and rigid body
movement of helix VI upon light activation (31). This was con-
firmed by Cys cross-linking andmetal-ion binding of these hel-
ices, which prevent activation of the rhodopsin-coupled G pro-
tein, transducin (31, 32). It is worthy of mention that the
strategy of engineered metal-ion binding sites between trans-
membrane helices applied to a number of peptide receptors
confirmed the proximity of the upper part of helices III and VI
and their relativemotion during receptor activation (33). Inter-
estingly, the maximal efficacy of metals was obtained when the
metal ion site was formed by amino acids in positions III:08 and
VI:16, which correspond to Met-3.32 and Val-6.51 of CCK2R,
respectively. A distance of about 8Å between theC carbons of
these two residues was found in CCK2R*, a value that is in
agreement with the optimal distance required for metal coor-
dination. Using a cysteine-reactive fluorophore incorporated
into mutants of a Gs-coupled GPCR, the 2-adrenoreceptor,
movements of the cytoplasmic sides of helices III and VI, rela-
tive to the membrane lipid bilayer, were directly detected upon
agonist activation (34). Data obtained with two GPCRs having
distant amino acid sequences, the 2-adrenoreceptor and the
parathyroid hormone receptor, suggested that the activation
mechanism that requires relative movement of helices III and
VI to one another is conserved amongGPCRs (32). The specific
role of the conserved Trp of the motif CWXPFF in helix VI
(Trp-6.48 in CCK2R) as a rotamer switch for GPCR activation
has been elegantly documented in rhodopsin using solid-state
magic angle spinning NMR measurements of rhodopsin and
metarhodopsin II (23). It was indeed shown that interactions
between the retinal and Trp-265 of rhodopsin contributes to
the maintenance of rhodopsin in the inactive state in the dark,
whereas disruption of this interaction under light activation
allows Trp-265 and helix VI to rotate and adopt the active con-
formation (23). It was also demonstratedwithmetarhodopsin II
that the packing interaction between Trp-265 and Gly-121 is
disrupted, a result consistentwithmotion of helix VI away from
helix III. In the current study with CCK2R, we observed an
increase of the distance between equivalent amino acids,
namely Trp-6.48 and Val-3.36 (23).
Concerning helix V, which undergoes a concerted rotation
with helix VII during CCK2R activation, identification of Phe-
5.47 as a key residue is in line with the concept that a conserved
Phe/Tyr residue in this helix (located at3 residues of a proline
and corresponding to Phe-5.47 in CCK2R) plays a critical role
in the activation switch. In ghrelin and2-adrenergic receptors,
mutation of this residue has been reported to decrease receptor
activity (30). Surprisingly, the mutation of Phe-5.47 in CCK2R
yielded a constitutively active receptor, and both TMD and
experimental results clearly ascribed a constraining role to helix
V, since themotion of Phe-5.47 andLeu-5.43 liberates the space
that allows Trp-6.48 and Tyr-6.52 to rotate.
With respect to helix VII, its role as an activation or coupling
TABLE 3
Pharmacological properties of CCK2Rmutants
Binding properties and biological potency of mutated CCK2R were determined as described under “Experimental Procedures.” Mutation factors (F) were calculated as Kd
(mutated CCK2R)/Kd (WT-CCK2R) or EC50 (mutated CCK2R/EC50 (WT-CCK2R). Emax values are expressed in percentage of wild-type CCK2R maximal inositol
accumulation in response to 1 M CCK. Results represent the means  S.E. of at least three independent experiments performed in duplicate on separately transfected
COS-7 cells.
CCK2R
CCK binding CCK-induced inositol phosphateproduction
High affinity Low affinity Bmax EC50 Fmut EmaxKd1 Fmut1 Kd2 Fmut2 High affinity Low affinity
nM nM pmol/106 cells nM
Wild type 0.37 0.02 1 2.8 0.3 1 0.89 0.05 2.3 0.2 0.34 0.05 1 100
R1.35A 1.30 0.30 4 22.0 3.0 8 0.19 0.04 0.66 0.05 2.2 0.4 6 100
Y1.39A 0.12 0.03 0.3 6.0 2.6 1.7 0.41 0.12 2.5 1.1 0.34 0.02 1 96
F120A 1.20 0.20 3 17.0 4.0 6 0.14 0.03 0.65 0.05 1.6 0.2 5 99
M3.32A 0.23 0.09 0.6 42.8 20.9 12.0 1.40 0.80 4.5 1.3 O.43 0.11 1 119
V3.36A 0.10 0.03 0.3 6.6 2.3 1.8 0.46 0.07 2.2 0.6 0.53 0.14 1.3 90
M4.57A 0.46 0.05 1.3 73.9 59.9 20.8 0.19 0.05 1.19 0.47 0.90 0.18 2.2 121
Y4.60F 3.20 0.50 9 21.0 4.0 8 0.28 0.05 0.82 0.18 3.7 0.4 11 97
Y4.60A 50.0 5.0 136 436 24 156 0.45 0.05 2.2 0.5 37.0 6.0 109 215
H207A 8.30 1.40 27 51.0 5.0 18 0.31 0.05 0.78 0.13 12.0 2.0 35 90
L5.42A 0.20 0.02 0.6 4.0 0.8 1.1 0.54 0.04 3.3 0.2 0.48 0.07 1.2 190
L5.43A 0.30 0.04 0.8 32.1 17.5 9.0 2.40 0.60 3.8 2.0 0.39 0.07 0.9 120
F5.47A 0.31 0.05 0.9 1.54 0.28 0.27 0.06 0.7 150
F6.44A 0.22 0.05 0.6 14.2 7.2 4.0 0.58 0.13 0.77 0.30 0.38 0.07 0.9 96
W6.48A 0.31 0.05 0.9 19.5 9.2 5.5 0.60 0.09 3.0 1.5 0.75 0.17 1.8 172
V6.51A 0.28 0.09 0.8 15.0 6.9 4.2 0.34 0.09 1.5 0.4 0.40 0.11 1.2 102
Y6.52A 0.25 0.05 0.7 3.9 1.6 1.0 0.63 0.13 2.4 0.8 0.32 0.09 0.8 127
N6.55A 12.0 1.0 32 114.0 5.0 41 0.17 0.06 0.62 0.04 11.0 1.0 32 89
R6.58A 28.0 2.0 76 0.49 0.04 22.0 4.0 65 100
H7.39A 0.56 0.20 1.5 18.3 1.2 5.2 0.07 0.06 1.7 1.4 2.84 0.57 6.8 90
Y7.43A 0.92 0.27 2.6 53.1 12.4 14.9 0.32 0.09 1.5 0.5 1.18 0.21 1.2 104
Y7.43F 0.29 0.14 0.8 29.0 21.1 8.1 0.80 0.32 9.3 5.2 0.52 0.03 1.2 140
S7.45A 0.73 0.10 2.0 1.80 0.09 0.24 0.09 0.7 75
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switch has been illustrated. For instance, in the C5a receptor,
motion of helix VII has been proposed to explain the activation
switch observed with mutants (35). Movement of the cytoplas-
mic interface of this helix during activation is supported by data
showing that the NPXXY motif is accessible to an antibody in
metarhodopsin, whereas it is not in rhodopsin maintained in
the dark (36). Furthermore, it has been shown that upon forma-
tion ofmetarhodopsin, the salt bridge betweenGlu-113 in helix
III and the protonated Schiff base formed by retinal and Lys-
296 in helix VII is disrupted, which requires movement of helix
VII relative to helix III (37). In CCK2R, we have noticed an
uppermovement of helix VII of about 2 Å. Such amovement, if
applied to rhodopsin helix VII, would cause disruption of the
Glu113–Lys296 salt bridge and would probably establish contact
betweenLys296 andGlu181 (37). TMDwithCCK2R showed that
the upper movement of helix VII starts once the Trp-6.48 side
chain has begun to rotate and the hydrogen bonding interaction
with Ser-7.45 is lost. Disruption of the hydrogen bond may be
an important event in the activation process of CCK2R, but the
fact that mutation of Ser-7.45 did not generate constitutive
activity also indicated that disruption of this hydrogen bond is
not sufficient for CCK2R activation. Asn-7.45 in histamine H1
receptor, the cognate residue of Ser-7.45, was reported to play a
role in receptor activation (38). Indeed, it was demonstrated
that in the H1 receptor, Asn-7.45 constrained Trp-6.48 in the
inactive g conformation through a hydrogen bonding inter-
action and that, unlike in CCK2R, disruption of this hydrogen
bond by leucine substitution leads to a constitutively active
receptor (38).
The critical role of helix IV in CCK2R activation is remarka-
ble. This helix does not undergo significant movement during
CCK2R°-CCK2R* conversion, but its distance with respect to
helix VI seems critical in CCK2R*, as supported by the dramatic
decrease of the distance between the two helices in CCK2R*
relative to theCCK2R° and the role played by theCCK-amide in
the maintenance of this proximity. Helix IV may therefore be
considered a part of the rigid body of the receptor and con-
tributes to the correct positioning of helix VI. The impor-
tance of helix IV as an anchoring point for peptidic ligand
binding has been documented for other peptide receptors. In
the CXCR4 chemokine receptor, urotensin II receptor, vaso-
pressin V1a receptor, and melanocortin-4 receptor, the res-
idue equivalent to Tyr-4.60 in CCK2R is critical for agonist
binding (39–42). However, with the current work on
CCK2R, this is the first example of a key role being ascribed
to helix IV in the control of the equilibrium between inactive
and active conformations.
Taken together, structural changes observed during CCK2R
activation are in line with those described or suggested with
other GPCRs using biochemical and biophysical techniques,
but they appear quantitatively smaller (28–30). Instead,
changes that accompany CCK2R activation are quantitatively
more comparable with those deduced from the recent crystal-
lization of a photoactivated, deprotonated intermediate of rho-
dopsin (43). Furthermore, our data point out that the role
played by some conserved amino acids in the activation process
is different in CCK2R relative to other members of the GPCR
family A. Hence, during activation, CCK2R undergoes confor-
mational changes that are shared by members of GPCR class A
but also appears to present divergent features, which may
account for its ligand and signaling selectivity. In the future,
studies onGPCRmechanism of activationwill have to take into
account the entire structure of the receptor, including the third
intracellular loop, the structure of which is dependent on the
relative position of helices V and VI as well as on binding of the
 subunit of the coupled G-protein.
It is worthy of note that several amino acids identified as
critical in the activation process of CCK2R have been previ-
ously mutated. For instance, the exchange of Met-3.32, Val-
3.36, and Leu-5.43 was shown to increase basal activity of
CCK2R in COS-7 cells (24, 44). Interestingly, in the mentioned
studies, partial agonist activity of PD-135,158, a molecule ini-
tially believed to be an antagonist, was increased on M4.57A
and W6.48A mutants, whereas it disappeared on F5.47A and
Y6.52A mutants. Such mutants were previously defined as “a
subgroup of activating mutations which facilitates receptor
isomerization to the active state and in parallel perturbs ligand
receptor interactions” (44). Our data provide a significant
advance, since they show how CCK2R can adopt the active
conformation on its own and how the peptide agonist, CCK,
binds to CCK2R* to stabilize it. Obviously, additional works
using biochemical and biophysical approaches are highly desir-
able to further verify the findings of the present study.
Last, this study with CCK2R illustrates how TMD, in con-
trast to ordinary molecular dynamics simulation, is a powerful
molecular modeling technique able to study conformational
conversion between inactive and active states of a complex
membrane protein such as a GPCR. Previously, TMD has been
successfully applied to study conformational transitions of
KcsA channel, chymotrypsin, and other proteins (27, 45, 46).
However, to our knowledge, analysis of CCK2R activation rep-
resents the first successful application of TMD to a GPCR.
Based on the findings from this study, TMD appears appropri-
ate to study, at the atomic level, the structural determinants
involved in the activation of a GPCR. Interestingly, the inter-
mediary receptor structures that can be identified and
extracted from the TMD trajectories can be used as targets for
ligand docking studies. Besides providing information of basic
scientific interest, it is expected that insight into the activation
and inactivation mechanism of GPCRs will be exploited in
structure-based drug discovery efforts.
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